9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance

Eur J Cancer. 1990;26(6):665-7. doi: 10.1016/0277-5379(90)90112-7.

Abstract

The intramolecular combination of 9-alkyl substitution in the anthracycline A-ring plus incorporation of the amino group of the daunosamine sugar within a morpholinyl ring led to the retention of almost complete activity against P-glycoprotein positive, multidrug resistant variants of a mouse mammary tumour line and a human small cell lung cancer line. Resistance factors were close to unity. These structural elements may prevent efflux by the P-glycoprotein multidrug transporter. The use of 9-alkyl, morpholinyl anthracyclines with resistance circumvention properties may have clinical application.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Aclarubicin / analogs & derivatives
  • Aclarubicin / therapeutic use
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Antibiotics, Antineoplastic / therapeutic use*
  • Carcinoma, Small Cell / drug therapy
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / therapeutic use
  • Drug Resistance
  • Humans
  • Lung Neoplasms / drug therapy
  • Mammary Neoplasms, Experimental / drug therapy
  • Membrane Glycoproteins / analysis
  • Mice
  • Neoplasm Proteins / analysis
  • Tumor Cells, Cultured / drug effects

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Adjuvants, Immunologic
  • Antibiotics, Antineoplastic
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • aclacinomycins
  • Aclarubicin
  • Doxorubicin
  • NSC 354646
  • 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin